Skip to main content

Table 2 Baseline demographics and clinical characteristics

From: Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study

 

Safety population (n = 351)

Faster infusion evaluable populationa(n = 337)

Demographics

Female, n (%)

279 (79.5)

268 (79.5)

Age, mean (SD), y

55.5 (11.5)

55.6 (11.4)

  Range

23-88

23-88

Age group, n (%)

  

  18-40 y

38 (10.8)

34 (10.1)

  41-64 y

244 (69.5)

236 (70.0)

  ≥ 65 y

69 (19.7)

67 (19.9)

Race, n (%)

  

  White

295 (84.0)

283 (84.0)

  African American

35 (10.0)

33 (9.8)

  Other

21 (6.0)

21 (6.2)

Weight, mean (SD), kg

84.9 (21.2)

84.9 (21.2)

  Range

47-156

47-156

Height, mean (SD), cm

165.0 (9.6)

165.0 (9.6)

  Range

130-198

130-198

RA clinical characteristics

Duration of RA, mean (SD), y

12.5 (9.7)

12.4 (9.6)

RA disease duration, n (%)

  

< 3 y

42 (12.0)

42 (12.5)

  3-4 y

39 (11.1)

38 (11.3)

  5-10 y

93 (26.5)

87 (25.8)

> 10 y

177 (50.4)

170 (50.4)

Prior rituximab treatment

No. of prior rituximab courses, n (%)

  

  0

306 (87.2)

293 (86.9)

  1

24 (6.8)

24 (7.1)

  2

21 (6.0)

20 (5.9)

Months since most recent rituximab course, n

45

44

  Mean (SD)

6.8 (0.9)

6.7 (0.9)

  Range

5-9

5-9

Medication history

No. of prior anti-TNF agents, n (%)

  

  0

4 (1.1)

4 (1.2)

  1

187 (53.3)

182 (54.0)

  2

116 (33.0)

108 (32.0)

  ≥ 3

44 (12.5)

43 (12.8)

Prior non–anti-TNF biologic DMARDs

  

  Abatacept

17 (4.8)

16 (4.7)

  Tocilizumab

12 (3.4)

12 (3.6)

MTX dose, mg/wk

  

  Mean (SD)

17.4 (4.7)

17.3 (4.7)

  Median (range)

17.5 (8–25)

17.5 (8–25)

Oral steroid use, n (%)

150 (42.7)

143 (42.4)

Oral steroid dose, mg/d

  

  Mean (SD)

7.2 (3.4)

7.3 (3.4)

  Median (range)

5 (2–25)

5 (2–25)

  1. Anti-TNF, anti–tumor necrosis factor; DMARD, disease-modifying antirheumatic drug; IQR, interquartile range; MTX, methotrexate; RA, rheumatoid arthritis; SD, standard deviation. aOf the 341 patients who received infusion 2, four were not included because medication volume was not recorded.